These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

774 related articles for article (PubMed ID: 36238280)

  • 1. Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy.
    Zhou S; Ren F; Meng X
    Front Immunol; 2022; 13():955944. PubMed ID: 36238280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy.
    Zhu Y; Zhang Y; Hu X; Wang M; Wang H; Liu Y
    J Cancer Res Clin Oncol; 2022 Dec; 148(12):3557-3566. PubMed ID: 35857126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations.
    Si J; Hao Y; Wei J; Xiang J; Xu C; Shen Q; Song Z
    BMC Pulm Med; 2023 May; 23(1):158. PubMed ID: 37147602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance.
    Li Y; Jiang H; Qian F; Chen Y; Zhou W; Zhang Y; Lu J; Lou Y; Han B; Zhang W
    Front Immunol; 2023; 14():1161718. PubMed ID: 37266427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of immune checkpoint inhibitors in advanced
    Hu J; Huang D; Wang Y; Li D; Yang X; Fu Y; Du N; Zhao Y; Li X; Ma J; Hu Y
    Front Immunol; 2022; 13():975246. PubMed ID: 36159795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of immune checkpoint inhibitors in post-TKI NSCLC patients harboring EGFR mutations.
    Sun S; Liu C; Duan C; Yu S; Zhang Q; Xu N; Yu B; Wu X; Wang J; Hu X; Yu H
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):2937-2949. PubMed ID: 35835883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant.
    Zhao L; Cai X; Chen D; Ye X; Gao M; Lu L; Su H; Su M; Hou M; Xie C
    Radiat Oncol; 2019 Dec; 15(1):3. PubMed ID: 31892337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases.
    Jiang T; Zhang Y; Li X; Zhao C; Chen X; Su C; Ren S; Yang N; Zhou C
    Eur J Cancer; 2019 Nov; 121():98-108. PubMed ID: 31569068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib in EGFR-mutant patients with EGFR-TKI-resistant NSCLC: a single-center retrospective study.
    Yin X; Liu X; Ren F; Meng X
    Cancer Immunol Immunother; 2024 May; 73(7):134. PubMed ID: 38758372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective study.
    Wang H; Xing R; Li M; Zhang M; Wei C; Zhang G; Niu Y; Ma Z; Yan X
    BMC Cancer; 2023 Mar; 23(1):289. PubMed ID: 36997925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
    Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
    JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Immune Checkpoint Inhibitors in Patients With EGFR Mutated NSCLC and Potential Risk Factors Associated With Prognosis: A Single Institution Experience.
    Bai M; Wang W; Gao X; Wu L; Jin P; Wu H; Yu J; Meng X
    Front Immunol; 2022; 13():832419. PubMed ID: 35296087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
    Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors.
    Ichihara E; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Ochi N; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Cancer Immunol Immunother; 2021 Jan; 70(1):101-106. PubMed ID: 32648165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer.
    Morimoto K; Yamada T; Sawada R; Azuma K; Goto Y; Harada T; Shiotsu S; Tamiya N; Chihara Y; Takeda T; Hiranuma O; Hasegawa I; Tanaka S; Yoshimura A; Iwasaku M; Tokuda S; Kim YH; Takayama K
    Cancer Immunol Immunother; 2023 Jun; 72(6):1699-1707. PubMed ID: 36617602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study.
    Kuribayashi T; Ohashi K; Nishii K; Ninomiya K; Tsubata Y; Ishikawa N; Kodani M; Kanaji N; Yamasaki M; Fujitaka K; Kuyama S; Takigawa N; Fujimoto N; Kubota T; Inoue M; Fujiwara K; Harita S; Takata I; Takada K; Okawa S; Kiura K; Hotta K
    J Cancer Res Clin Oncol; 2024 Feb; 150(2):89. PubMed ID: 38347279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
    Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
    Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
    Magnuson WJ; Lester-Coll NH; Wu AJ; Yang TJ; Lockney NA; Gerber NK; Beal K; Amini A; Patil T; Kavanagh BD; Camidge DR; Braunstein SE; Boreta LC; Balasubramanian SK; Ahluwalia MS; Rana NG; Attia A; Gettinger SN; Contessa JN; Yu JB; Chiang VL
    J Clin Oncol; 2017 Apr; 35(10):1070-1077. PubMed ID: 28113019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved survival and intracranial tumor control of EGFR-mutated NSCLC patients with newly developed brain metastases following stereotactic radiosurgery and EGFR-TKI: a large retrospective cohort study and meta-analyses.
    Kuan AS; Chiang CL; Wu HM; Yang HC; Chen CJ; Lin CJ; Guo WY; Pan DH; Chung WY; Lee CC
    J Neurooncol; 2023 Sep; 164(3):729-739. PubMed ID: 37721662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
    Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.